Insmed (INSM) investor relations material

Commercial performance and operational excellence

• Achieved 44% growth in the most recent quarter, exceeding industry analogs due to operational excellence and early investments in trial design, execution, and disease awareness.

• Revenue guidance set at a minimum of $1 billion for the year, positioning the launch among the top 25 in the sector.

• Over 90% of payers are approving prescriptions through specialty pharmacies, with refill rates exceeding industry averages.

• Patient support program inLighten has over 80% enrollment, significantly above industry norms, contributing to strong patient retention.

• Confident in achieving $5 billion peak revenue, driven by chronic use and expanding patient population.

Patient compliance, education, and market expansion

• Discontinuation rates are better than benchmarks like statins, asthma, and COPD, with no underlying concerns identified.

• Ongoing education for physicians and patients emphasizes adequate time on therapy and the product’s favorable safety profile.

• Organic patient growth in Q1 reached 6,300, with steady new patient additions expected to drive annual revenue targets.

• Total addressable market (TAM) estimated at 500,000 diagnosed patients, with potential for further growth from underdiagnosed COPD and asthma populations.

• Disease awareness campaigns and real-world data analyses are expected to identify additional eligible patients, with impact from these efforts likely starting next year.

Financial guidance and international strategy

• Revenue guidance provided early due to strong initial performance, with updates contingent on additional quarters of data.

• Confident that current U.S. diagnosed patients alone can support both $1 billion and $5 billion sales targets.

• International expansion in Japan is underway, with regulatory and pricing processes ongoing; revenue contribution expected from 2027.